Some data suggest inhibiting EZH2 increases the likelihood of eradicating CML LSCs with TKI-therapy whilst sparing normal stem cells [99] but this finding needs confirmation. The gene discussed is EZH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.